(Circulation. 1995;91:1659-1668.)
© 1995 American Heart Association, Inc.
Articles |
Predictors of 30-Day Mortality in the Era of Reperfusion for Acute Myocardial Infarction
Results From an International Trial of 41 021 Patients
From the Departments of Community and Family Medicine (Biometry) (K.L.L.) and Medicine (Cardiology) (L.H.W., R.M.C.), Duke University Medical Center, Durham, NC; the Department of Cardiology, Cleveland (Ohio) Clinic Foundation (E.J.T.); the Department of Medicine (Cardiology), University of Washington, Seattle (W.D.W.); Hospital Clinic I, Barcelona, Spain (A.B.); Clinique Universitaire St Luc, Bruxelles, Belgium (J.C.); the Thoraxcenter, Erasmus Universiteit, Rotterdam, The Netherlands (M.S.); the Department of Cardiovascular Medicine, Flinders Medical Center, Bedford Park, SA, Australia (P.A.); and the Department of Cardiology, University of Leuven (Belgium) (F. Van de W.).
Correspondence to Kerry L. Lee, PhD, Associate Professor, Biometry Division, Community and Family Medicine, Box 3363, Duke University Medical Center, Durham, NC 27710.
 |
Abstract |
|---|
 Top Abstract IntroductionMethods Results Discussion References |
|---|
Background Despite remarkable advances in the treatment of acute myocardial infarction, substantial early patient mortality remains. Appropriate choices among alternative therapies and the use of clinical resources depend on an estimate of the patient's risk. Individual patients reflect a combination of clinical features that influence prognosis, and these factors must be appropriately weighted to produce an accurate assessment of risk. Prior studies to define prognosis either were performed before widespread use of thrombolysis or were limited in sample size or spectrum of data. Using the large population of the GUSTO-I trial, we performed a comprehensive analysis of relations between baseline clinical data and 30-day mortality and developed a multivariable statistical model for risk assessment in candidates for thrombolytic therapy.
Methods and Results For the 41 021 patients enrolled in GUSTO-I,
a randomized trial of four thrombolytic strategies, relations between
clinical descriptors routinely collected at initial presentation,
and death within 30 days (which occurred in 7% of the population) were
examined with both univariable and multivariable analyses. Variables
studied included demographics, history and risk factors, presenting
characteristics, and treatment assignment. Risk modeling was performed
with logistic multiple regression and validated with bootstrapping
techniques. Multivariable analysis identified age as the most
significant factor influencing 30-day mortality, with rates of 1.1% in
the youngest decile (<45 years) and 20.5% in patients >75 (adjusted
2=717, P<.0001). Other factors most
significantly associated with increased mortality were lower systolic
blood pressure (2=550, P<.0001),
higher Killip class (2=350, P<.0001),
elevated heart rate (2=275, P<.0001),
and anterior infarction (2=143,
P<.0001). Together, these five characteristics contained
90% of the prognostic information in the baseline clinical data. Other
significant though less important factors included previous myocardial
infarction, height, time to treatment, diabetes, weight, smoking
status, type of thrombolytic, previous bypass surgery, hypertension,
and prior cerebrovascular disease. Combining prognostic variables
through logistic regression, we produced a validated model that
stratified patient risk and accurately estimated the likelihood of
death.
Conclusions The clinical determinants of mortality in patients treated with thrombolytic therapy within 6 hours of symptom onset are multifactorial and the relations complex. Although a few variables contain most of the prognostic information, many others contribute additional independent prognostic information. Through consideration of multiple characteristics, including age, medical history, physiological significance of the infarction, and medical treatment, the prognosis of an individual patient can be accurately estimated.
Key Words: myocardial infarction • prognosis • risk factors • thrombolysis
|
Introduction |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Substantial advances in the treatment of acute myocardial infarction (MI) have occurred over the past several years as a result of important observations in basic myocardial research and through the vital evaluative mechanism of randomized clinical trials.1 2 3 4 5 6 7 8 9 10 Practitioners now have a variety of treatment strategies available, especially for patients with ST-segment elevation, to restore obstructed coronary blood flow and interrupt the evolving myocardial event. Despite therapeutic advances, recent large-scale randomized clinical trials report 6% to 9% early mortality rates (30 to 35 days), even for patients receiving thrombolytic therapy within 6 hours of symptom onset.11 12 13 14 Often, choices among alternative therapies or decisions regarding the allocation of clinical resources are based on an assessment of patient risk. Careful attention to pivotal factors that increase the risk of early mortality might illuminate the role of second-tier interventions or adjunctive pharmacotherapeutics that would further lower the fatality rate of acute MI.
To be broadly useful, a risk-assessment algorithm should include all clinically relevant prognostic indicators and should be derived from a population that represents the types of patients seen in clinical practice so that stable estimates of true risk relations can be assessed. A useful model should appropriately weight clinically relevant predictors and be validated in a population with a broad spectrum of patients and hospital settings, in which risk profiles may soon be required. Though many studies have attempted to define the prognosis of patients with MI and/or provide risk algorithms,15 16 17 18 19 20 21 22 23 they were performed before the widespread use of thrombolytic agents15 16 17 18 19 or were limited in sample size, diversity of medical care systems, or spectrum of clinical data.
Using the large population of the international Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial (41 021 patients admitted to 1081 hospitals in 15 countries),14 we attempted to provide a comprehensive analysis of relations between baseline clinical factors and 30-day mortality after intravenous thrombolytic therapy. The goal was to develop a multivariable statistical model with patient data routinely collected at initial presentation that would be clinically useful in managing patients who are candidates for thrombolytic therapy.
|
Methods |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Patient Population
The GUSTO-I trial enrolled 41 021 patients with acute MI presenting with ST-segment elevation (within 6 hours of symptom onset) between December 27, 1990, and February 22, 1993. The design and data collection methods of GUSTO-I were described previously.14 Patients were randomized over the telephone, with selected baseline characteristics recorded to ensure eligibility. Exclusion criteria included a history of stroke, active or recent bleeding history or major coagulation abnormality, recent trauma or major surgery, noncompressible vascular punctures, and previous treatment with streptokinase or anistreplase (because of possible allergic reactions). There were no restrictions based on age, presentation in cardiogenic shock, or prior bypass surgery.
Treatments
Qualifying patients were randomly allocated to one
of four
treatment strategies: streptokinase 1.5 million U over 60 minutes with
subcutaneous heparin 12 500 U twice daily, beginning 4 hours after the
start of thrombolytic therapy; streptokinase 1.5 million U over 60
minutes with intravenous heparin bolus of 5000 U and then 1000 U/h,
with dose adjustment to maintain an activated partial thromboplastin
time of 60 to 85 seconds; accelerated tissue-plasminogen activator
(TPA) bolus of 15 mg and then infusion of 0.75 mg/kg (up to 50 mg) over
30 minutes and 0.5 mg/kg (up to 35 mg) over the next 60 minutes,
accompanied by the same intravenous heparin regimen; or a combination
of intravenous TPA (1.0 mg/kg over 60 minutes, not to exceed 90 mg,
with 10% given as a bolus) and streptokinase (1.0 million U over 60
minutes) given concurrently but through separate catheters, accompanied
by the same intravenous heparin regimen.14
Baseline Clinical Information
Baseline clinical data were
collected on all patients with a
standard data collection form. Specific written instructions and
definitions for each variable were provided to all sites for use in
completing the forms. Definitions of the clinical variables in this
trial were used in previous studies.14 24 Extensive
quality control checks have been used at the time of data entry, and
missing or questionable answers were queried. A sample of 12% of the
forms was audited by a comparison of the data on the form with hospital
medical records.
End-Point Assessment
The primary end point of the trial was
death from any cause
within 30 days of randomization. The study coordinator at each site
recorded mortality information for patients who died in the hospital.
Mortality data after discharge but within 30 days were obtained by a
postcard returned by patients or their families. When no postcard was
received, follow-up status was determined over the telephone.
Statistical Methods
Baseline characteristics of study
patients were summarized in
terms of frequencies and percentages for categorical variables and by
the median and 25th and 75th percentiles for continuous variables. A
logistic multiple regression model25 26 was used to
examine individual and joint relations between baseline clinical
characteristics and the binary outcome of death within 30 days of
randomization. For continuous clinical variables, we examined the shape
and strength of the relation between individual variables and 30-day
mortality by use of a flexible model-fitting approach involving cubic
spline functions (cubic
polynomials).27 28 29 30 31
These functions
were graphically and statistically examined to assess the assumption of
this regression model that patient characteristics are linearly related
to the log odds of the outcome event (30-day mortality). Where
relations were nonlinear, their shape was characterized with spline
functions. Determining how variables should be modeled was an important
step in characterizing prognostic relations and identifying which
variables were most strongly related to short-term mortality. We also
examined whether the prognostic relation of any important variable
differed for particular levels of other important descriptors (ie, we
tested for interactions among the prognostic clinical variables).
Among the array of clinical characteristics considered potential predictor variables in the modeling analyses were occasional patients with missing values. Although a full set of analyses was performed in patients with complete data for all the important predictor variables (92% of the study patients), the subset of patients with one or more missing predictor variables had a higher mortality rate than the other patients, and excluding those patients could lead to biased estimates of risk. To circumvent this, a method for simultaneous imputation and transformation of predictor variables based on the concepts of maximum generalized variance and canonical variables was used to estimate missing predictor variables and allow analysis of all patients.33 34 The iterative imputation technique conceptually involved estimating a given predictor variable on the basis of multiple regression on (possibly) transformed values of all the other predictor variables. End-point data were not explicitly used in the imputation process. The computations for these analyses were performed with S-PLUS statistical software (version 3.2 for UNIX32 ), using a modification of an existing algorithm.33 34 The imputation software is available electronically in the public domain.33
The full study population was used in the model development process, and the predictive performance of the model was internally validated through cross validation and bootstrapping.35 36 37 38 39 First, 10-fold cross validation was performed: the model was fitted on a randomly selected subset of 90% of the study patients, and the resulting fit was tested on the remaining 10%. This process was repeated 10 times to estimate the extent to which the predictive accuracy of the model (based on the entire sample) was overoptimistic. Second, for each of 100 bootstrap samples (samples of the same size as the original population but with patients drawn randomly, with replacement, from the full study population), the model was refitted and then tested on the original sample, again to estimate the degree to which the predictive accuracy of the model would be expected to deteriorate when applied to an independent sample of patients.39 The software used for model validation is also available electronically in the public domain.40
The measure of predictive discrimination used to characterize model performance, in both the original sample and the validation samples, was the area under the receiver operating characteristic curve.41 This index measures the concordance of predictions with actual outcomes (how well the predictions rank order patients with respect to their outcomes) and is a simple transformation of Somer's Dxy rank correlation between the model predictions and actual outcomes.42 Calibration of the model predictions was assessed by comparison of the average model prediction to the observed mortality rate across deciles of risk and among specific subgroups of patients with different risk levels.43
|
Results |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
Thirty-day mortality status was known in 40 830 patients (99.5%). Table 1
summarizes the baseline clinical
characteristics of this population. The demographics and clinical
characteristics of these patients encompass the spectrum of acute MI
patients who present with ST-segment elevation and are considered
eligible for thrombolytic therapy based on GUSTO-I entry criteria. As
previously reported,14 there were no differences in
baseline characteristics among the four treatment groups in the trial.
A total of 2851 patients (7.0%) died within 30 days of study
enrollment. Thirty-nine percent of the deaths (1125) occurred within 24
hours; more than half (55%) occurred within 48 hours of
randomization.
|
In Table 2, 30-day mortality rates are reported for each
categorical baseline characteristic, accompanied by univariable
2 statistics and unadjusted odd ratios (ORs),
reflecting the degree of risk stratification associated with each
characteristic when considered alone. The most significant factor among
these variables was Killip class at enrollment. Although relatively few
patients presented in Killip class III or IV (2%), their mortality
rate was very high. The other more significant univariable predictors
of higher mortality were female sex, anterior wall MI, history of
previous MI, and history of diabetes. Smoking status was a highly
significant univariable predictor, with current or prior smoking
associated with lower mortality.
|
Fig 1 shows the univariable prognostic relations for
continuous baseline characteristics. The most significant prognostic
factor among this group of variables was age, where beyond 60 years
there was a dramatic effect of increasing age on mortality. A strong
prognostic relation was also present for systolic blood pressure,
notably in the range below 120 mm Hg. A similar but less significant
pattern existed for diastolic blood pressure. Heart rate at entry
displayed a significant U-shaped relation, with elevated
mortality at very low and at high heart rates. Weaker prognostic
relations were demonstrated for both weight and height, with lighter
and shorter patients exhibiting slightly higher risk. In patients who
were treated more than 2 hours from symptom onset, the risk of
mortality gradually increased with longer time to treatment. Compared
with the other clinical factors in Fig 1, the relation between
time to
treatment and mortality was less significant.
|
In the multivariable analysis, many characteristics significantly
associated with mortality in univariable analysis remained
important (Table 3). Variables that were not
significant, however, included prior angina, prior angioplasty,
diastolic blood pressure, and family history of coronary heart disease.
Female sex (P=.043) and enrollment in the United States
(P=.047) had borderline relations with outcome after
adjustment for the other prognostic variables and thus were not
included in the final multivariable model. The variable demonstrating
the strongest independent relation with 30-day mortality was age. Even
after adjustment for the other important clinical factors, patients at
the upper quartile of the age distribution in this population (70
years) were nearly four times more likely to die within 30 days than
patients at the lowest quartile (52 years; adjusted OR, 3.88; 95% CI,
3.52 to 4.28). The other more significant independent predictors of
mortality were systolic blood pressure, Killip class, heart rate, and
MI location.
|
Only one interaction among these factors was significant to the degree that it was appropriate to include in the model—the interaction between age and Killip class. The prognostic effect of age was reduced somewhat among patients with a more severe Killip class at entry, and conversely, risk differences among Killip classes were less in older patients.
Fig 2 shows adjusted ORs for mortality for each of the
variables in the final multivariable model. The ORs were most dramatic
for factors such as age and Killip class, each exhibiting a highly
significant relation with mortality in the multivariable regression
analysis. After adjustment for all other factors, the OR associated
with Killip class III versus I for an average-age patient was 4.37
(95% CI, 3.34 to 5.71), whereas the OR for Killip class IV versus I
was 7.86 (95% CI, 5.88 to 10.49).
|
The model formulation that includes all factors in Table 3
is given in
the "Appendix." With the coefficients in this model and the ORs in
Fig 2, relative effects of various clinical factors can be
quantified.
For example, each additional year of age in Killip class I patients
imparts a risk equal to a 2 mm Hg reduction in systolic blood pressure
(for patients presenting with systolic blood pressures below 120
mm Hg) or to treating patients 45 minutes later. An additional 7 years
of age confers a risk similar to the difference between an inferior and
anterior MI, and the risk reduction associated with use of accelerated
TPA is equivalent to a reduction in age of about 3 years.
The index of predictive discrimination for this model, namely the area under the receiver operating characteristic curve, was 0.836, reflecting excellent ability of the model to discriminate between patients who do and do not have a fatal event within 30 days.
Fig 3 shows the calibration (reliability) of the
model predictions. Patients were divided into deciles of risk according
to their model predictions, and the observed mortality rate among the
patients in each decile was calculated and plotted against the average
predicted probability. The points all fell very close to the 45° line
(perfect calibration), demonstrating excellent calibration of the
predictions from this model. Table 4 illustrates the
same concept for several arbitrarily chosen subgroups defined by
specific clinical characteristics, namely sex, age, infarct location,
and Killip class. The average predicted mortality for patients in each
of these subgroups (even subgroups defined by a factor not included in
the multivariable model, such as male and female patients) coincided
very closely with the observed mortality, again reflecting excellent
calibration of the model predictions. Results of the internal
validation revealed very little overoptimism in the predictive
discrimination of the model. The correction to the receiver operating
characteristic area determined by cross validation was only 0.002
(reducing the value from 0.836 to 0.834). The bootstrapping technique
produced exactly the same correction. As a result, the calibration
curve in Fig 3 did not need an optimism correction.
|
|
A perspective on the overall contribution of various components of the
baseline clinical data to the prediction of mortality can be obtained
by use of the global 2 statistic from the
logistic model as an index of prognostic information and a comparison
of this index from the full model containing all the variables listed
in Table 3 with reduced models containing a smaller number of
variables. The likelihood ratio 2 statistic for a
model containing all of the prognostic factors in Table 3 was
4379. In
contrast, this statistic for a model containing age alone was 2099,
meaning that age provides nearly half the prognostic information.
Adding other variables provides an increased proportion of information;
combining age, systolic blood pressure, Killip class, heart rate,
infarct location, and age-by-Killip-class interaction provides
approximately 90% of the total prognostic information contained in
this array of baseline clinical characteristics.
|
Discussion |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
The clinical determinants of mortality in patients treated with thrombolytic therapy for ST-segment elevation within 6 hours of symptom onset are complex and multidimensional. Much of the important prognostic information was contained in the patient's age, location of the infarction, and physiological characteristics representing the severity of the derangement in myocardial function. Another tier of variables reflecting the circumstances under which the infarction was treated (eg, time to treatment and type of thrombolytic therapy) also exerted an independent influence, but the physiological variables were much more important. Although a few variables contained a large portion of the prognostic information, numerous factors contributed independent prognostic information in a sample size this large. The nature of the relations between many of the attributes and mortality added complexity because several continuous variables showed a nonlinear relation with the risk of death. In addition, the presence of interactions (eg, age and Killip class) added further complication to the analysis and interpretation of the model.
Statistical Issues
The goal of this analysis was to use
statistical methods to
model the medical issues as closely as possible. The use of cubic
spline
functions27 28 29 30 31
in conjunction with logistic
regression25 26 permitted joint assessment of
relations
between baseline characteristics and outcome that would not be possible
with subgrouping methods or other less sophisticated approaches.
Perhaps most importantly, this analysis clearly demonstrated the
imprecision of traditional subgroup analyses. For example, any age
subgroup (such as those over or under age 75) would include patients
who have markedly different prognoses. Furthermore, although a simple
division into men and women of different ages may stratify prognosis
into groups with different average survival rates (eg, men <70 years
versus women >70 years), the presence or absence of multiple other
characteristics could place an individual patient within this broadly
defined subgroup at a dramatically different risk. A multivariable
model that takes all factors into account and weights them
appropriately can therefore be of great clinical value in estimating
risk for an individual patient.
The methods used for internal validation of the model represent a rigorous test of the capability of the prediction algorithm. The results of these analyses suggest that the model should perform well in other similarly defined patient populations.
Demographics
Age has been increasingly recognized as a
critical determinant of
outcome in patients with acute ischemic heart disease. The relation was
relatively flat until age 60, when the risk of death accelerated
dramatically. These results are consistent with the report of the GISSI
2/International trial,12 although the larger number of
patients in the GUSTO-I trial allowed a more accurate characterization
of the relation across the entire age range.
Importantly, after adjustment for multiple other baseline characteristics, female sex was only a marginally independent prognostic factor (P=.043). Most previous studies8 44 45 46 found that when other baseline characteristics were adjusted for, the impact of sex was weakened but not eliminated; our conclusion sheds new light on this issue. In a comparable study of thrombolytic patients, other clinical factors also negated the independent effect of sex, although that study involved a much smaller number of patients and the OR for mortality in women was 1.31, even after the degree of obstructive coronary disease and left ventricular function were taken into account.44
Both heavier and taller patients were generally at lower risk for death, which was an unexpected and unexplained finding. Body mass index, a measure of the degree of obesity, was not as strongly related to outcome as either height or weight individually.
Hemodynamics and Infarct Site
Heart rate on admission is
frequently overlooked as an important
prognostic indicator. Patients with significant sinus tachycardia or
bradycardia on hospital admission had an increased risk of death.
Previous studies have identified sinus tachycardia as an independent
prognostic factor,47 presumably because it
represents activation of the sympathetic nervous system as a
consequence of infarction size. The physiological significance of
bradycardia may represent a variety of underlying
pathophysiological problems, ranging from conduction system
disturbances to agonal rhythms.
Systolic blood pressure is a critical factor. It is no surprise that hypotension was associated with a decrease in survival, but the level at which prognosis began to decline (120 mm Hg) is somewhat higher than expected. We could not find an effect of elevated blood pressure on survival. Many patients with extreme elevations of systolic blood pressure were excluded from GUSTO-I because of concern about the risk of intracranial hemorrhage, but 602 patients with a systolic blood pressure exceeding 180 mm Hg were included.
The relation between outcome and location of infarction is complicated. Multiple previous studies have reported that patients with anterior infarction have the highest risk of death,47 48 49 and isolated inferior infarction has been associated with the lowest risk. A detailed analysis from the GISSI I trial showed that the number of leads with ST-segment elevation was more important than infarction location,50 but ECG information from GUSTO-I is not yet available to confirm this analysis. We found that infarct location other than simple inferior or anterior infarctions had an intermediate prognosis.
Medical History
Several baseline features previously
identified as important
prognostic factors were again shown to be important predictors of
mortality in this analysis. Patients with prior MI have been shown
to be at increased risk of subsequent death in multiple previous
studies.16 Similarly, peripheral and cerebral vascular
diseases have been associated with more extensive
atherosclerosis.51 52 Diabetes was a major risk
factor for
death; recent studies have shown that patients with diabetes have more
extensive coronary atherosclerosis and worse left ventricular
function.53 54 A history of hypertension was also
associated with increased risk, although the strength of the relation
was much less than that of diabetes. At least a portion of the
increased risk may be due to heightened risk of stroke.
The influences of smoking, family history, and elevated cholesterol were paradoxical: they were associated with lower mortality despite being traditional risk factors for coronary artery disease. Several other studies also reported lower mortality in patients with a history of smoking.21 55 56 We presume that these relations are mediated by the association of these risk factors with premature atherosclerosis and thrombotic occlusion: the acute event occurs in a younger patient with less overall atherosclerosis and other comorbidity or is precipitated by a lesser stimulus, which may respond better to thrombolytic therapy. Despite this construct, we were unable to demonstrate that adjustment for other noninvasive measures of severity of illness completely explained the more benign prognosis of patients who were current or past smokers. Detailed assessment of coronary angiographic findings will be required to understand these relations more clearly.
The influences of prior percutaneous coronary angioplasty and coronary bypass grafting are complicated. Because most patients undergoing initial angioplasty have single-vessel disease, it is not surprising that they have a better prognosis than those who have an array of single-, double-, and triple-vessel disease. No previous studies included enough patients with prior angioplasty to allow comparison. The negative prognostic implications of prior coronary artery bypass grafting probably reflect the presence of more left ventricular dysfunction and multivessel coronary disease, leaving patients at increased risk of adverse outcomes in the setting of an acute event.
Modifiable Factors
Of the predictors of adverse outcome that
can be modified, time
from symptom onset to hospital arrival or treatment is the most
important. After adjustment for other factors in the model, each
additional hour was associated with a measurable increase in the risk
of death. This relation, however, was not linear for reasons that are
unclear.
After adjustment for other baseline characteristics, treatment in the United States (compared with other countries) was marginally associated with a better prognosis. The small difference (P=.047) was not enough to make a worthwhile contribution to the prediction of risk for the individual patient.
After adjustment for all known prognostic factors, the favorable effect of treatment with accelerated TPA and intravenous heparin remained significant compared with other treatment strategies. This consistency of the unadjusted and adjusted treatment comparisons is expected in such a large randomized trial.
Limitations
These results pertain only to patients admitted
to the hospital
with ST-segment elevation within 6 hours of symptom onset without
contraindications to thrombolytic therapy who are treated with
thrombolytic therapy. Recent registries and trials have described many
MI patient groups that have a higher risk of death than those in this
analysis. Patients with contraindications to thrombolytic therapy
have the highest mortality,57 and those with an acute MI
without ST-segment elevation have an intermediate risk.58
Though many of the same factors identified in this analysis would
be expected to relate to mortality, the quantitative relations
described here may not apply.
Additional clinical measurements not included in these analyses would also be expected to add to the prognostic model, especially additional ECG and angiographic information. Recent studies show that detailed measures of ST-segment elevation and T-wave height may provide substantial information about prognosis,50 59 independent of infarction location or other physiological factors. Also, coronary anatomy,60 left ventricular function,61 and patency and degree of mitral regurgitation62 would be expected to play major roles in determination of prognosis. Because most patients with acute ischemic disease do not undergo acute cardiac catheterization, using this information for risk assessment would not be meaningful in most patients. However, the information available from the GUSTO-I angiographic substudy63 provides insight into the pathophysiological basis for the risks associated with various baseline characteristics.
Conclusions
Careful modeling of 30-day mortality, using the
large population
of GUSTO-I patients and data routinely collected at initial
presentation, has yielded a method to accurately predict short-term
risk in individual patients. This risk-assessment algorithm should be
useful clinically in managing patients who are candidates for
thrombolytic therapy. Many prognostic factors identified in this
analysis cannot be modified, but the importance of early detection
and treatment of MI remained evident: even after adjustment for
physiological measures of hemodynamic deterioration, time to treatment
and type of thrombolytic therapy remained independent prognostic
factors. Only by considering the effect of multiple characteristics,
including age, medical history, physiological significance of the
current event, and medical treatment, can the prognosis of an
individual patient be estimated with confidence.
|
Acknowledgments |
|---|
This study was funded by grants from Bayer, CIBA-Corning, Genentech, ICI Pharmaceuticals, and Sanofi Pharmaceuticals.
Risk Model for 30-Day Mortality
Probability of
death within 30 days=1/[1+exp (-L)],
where L=3.812+0.07624 age-0.03976 minimum (SBP,
120)+2.0796 [Killip
class II]+3.6232 [Killip class III]+4.0392
[Killip class
IV]-0.02113 heart rate+0.03936 (heart
rate-50)+-0.5355
[inferior MI]-0.2598 [other MI location]+0.4115
[previous
MI]-0.03972 height+0.0001835
(height-154.9)+3-0.0008975
(height-165.1)+3+0.001587
(height-172.0)+3-0.001068
(height-177.3)+3+0.0001943
(height-185.4)+3+0.09299 time to
treatment-0.2190
[current smoker]-0.2129 [former smoker]+0.2497
[diabetes]-0.007379 weight+0.3524 [previous
CABG]+0.2142
[treatment with SK and intravenous heparin]+0.1968
[treatment with
SK and subcutaneous heparin]+0.1399 [treatment with combination
TPA
and SK plus intravenous heparin]+0.1645 [hx of
hypertension]+0.3412
[hx of cerebrovascular disease]-0.02124
age · [Killip class
II]-0.03494 age · [Killip class III]-0.03216
age · [Killip class IV].
Explanatory notes.
1. Brackets are interpreted as [c]=1 if the patient falls into category c, [c]=0 otherwise.
2. (x)+=x if x>0, (x)+=0 otherwise.
3. For systolic blood pressure (SBP), values >120 mm Hg are truncated at 120.
4. For time to treatment, values <2 hours are truncated at 2.
5. The measurement units for age are years; for blood pressure, millimeters of mercury; for heart rate, beats per minute; for height, centimeters; for time to treatment, hours; and for weight, kilograms.
6. "Other" MI location refers to posterior, lateral, or apical but not anterior or inferior.
7. CABG indicates coronary artery bypass grafting; SK, streptokinase; and hx, history.
Received May 12, 1994; revision received September 29, 1994; accepted October 14, 1994.
|
References |
|---|
|
TopAbstractIntroductionMethods Results Discussion References |
|---|
1. Kennedy JW, Martin GV, Davis KB, Maynard C, Stadius M, Sheehan FH, Ritchie JL. The Western Washington Intravenous Streptokinase in Acute Myocardial Infarction Randomized Trial. Circulation. 1988;77:345-352.
2. Gruppo Italiano per lo Studio della Streptochinasi Nell-Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-401. [Medline] [Order article via Infotrieve]
3. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360. [Medline] [Order article via Infotrieve]
4. Wilcox RG, von der Lippe G, Olsson CB, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 1988;2:525-530. [Medline] [Order article via Infotrieve]
5. The AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction. Lancet. 1988;1:545-549. [Medline] [Order article via Infotrieve]
6. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O'Neill WW, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987;317:581-588. [Abstract]
7.
The TIMI Research Group. Immediate versus delayed
catheterization and angioplasty following thrombolytic therapy for
acute myocardial infarction. JAMA. 1988;260:2849-2858.
8.
Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS,
Kudenchuk PJ, Eisenberg M. Prehospital-initiated versus
hospital-initiated thrombolytic therapy: the Myocardial Infarction
Triage and Intervention Trial. JAMA. 1993;270:1211-1216.
9.
Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe
J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE,
Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW, for the Primary
Angioplasty in Myocardial Infarction Study Group. A comparison of
immediate angioplasty with thrombolytic therapy for acute myocardial
infarction. N Engl J Med. 1993;328:673-679.
10. White HD, Norris RM, Brown MA, Takayama M, Maslowski A, Bass NM, Ormiston JA, Whitlock T. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987;317:850-855. [Abstract]
11. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet. 1990;336:65-71. [Medline] [Order article via Infotrieve]
12. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71-79. [Medline] [Order article via Infotrieve]
13. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1993;339:753-770.
14.
The GUSTO-I Investigators. An international randomized trial
comparing four thrombolytic strategies for acute myocardial infarction.
N Engl J Med. 1993;329:673-682.
15. Sanz G, Castaner A, Betriu A, Magrina J, Roig E, Coll S, Pare JC, Navarra-Lopez F. Determinants of prognosis in survivors of myocardial infarction. N Engl J Med. 1982;306:1065-1070.[Abstract]
16. Norris RM, Brandt PWT, Caughey DE, Lee AJ, Scott PJ. A new coronary prognostic index. Lancet. 1969;1:274-278. [Medline] [Order article via Infotrieve]
17.
Moss AJ, DeCamilla J, Davis H, Bayer L. The early
posthospital phase of myocardial infarction: prognostic stratification.
Circulation. 1976;54:58-64.
18. The Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction from the Multicenter Post-Infarction Research Group. N Engl J Med. 1983;309:331-336. [Abstract]
19. Dubois C, Pierard LA, Albert A, Smeets J-P, Demoulin J-C, Boland J, Kulbertus HE. Short-term risk stratification at admission based on simple clinical data in acute myocardial infarction. Am J Cardiol. 1988;61:216-219. [Medline] [Order article via Infotrieve]
20. Hillis DK, Forman S, Braunwald E, for the Thrombolysis in Myocardial Infarction (TIMI) Phase II Coinvestigators. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1990;16:313-315. [Abstract]
21.
Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A,
Schweiger M, Cabin H, Davison R, Miller D, Solomon R, Knatterud GL, for
the TIMI Investigators. Predictors of early morbidity and mortality
after thrombolytic therapy of acute myocardial infarction: analyses of
patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI)
Trial, Phase II. Circulation. 1992;85:1254-1264.
22. Maynard C, Weaver D, Litwin PE, Martin JS, Kudenchuk PJ, Dewhurst TA, Eisenberg MS, Hallstrom AP, Chambers J, for the MITI Project Investigators. Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention Project). Am J Cardiol. 1993;72:877-882. [Medline] [Order article via Infotrieve]
23.
Volpi A, DeVita C, Franzosi MG, Geraci E, Maggioni AP, Mauri
F, Negri E, Santoro E, Tavazzi L, Tognoni G, for the Ad hoc Working
Group of the Gruppo Italiano per lo Studio della Sopravvivenza
nell-Infarto Miocardico (GISSI-2) Data Base. Determinants of 6-month
mortality in survivors of myocardial infarction after thrombolysis:
results of the GISSI-2 data base. Circulation. 1993;88:416-429.
24.
Califf RM, Topol EJ, Stack RS, Ellis SG, George BS, Kereiakes
DJ, Samaha JK, Worley SJ, Anderson JL, Harrelson-Woodlief L, Wall TC,
Phillips HR III, Abbottsmith CW, Candela RJ, Flanagan WH, Sasahara AA,
Mantell SJ, Lee KL, for the TAMI Study Group. Evaluation of combination
thrombolytic therapy and timing of cardiac catheterization in acute
myocardial infarction: results of Thrombolysis and Angioplasty in
Myocardial Infarction, phase 5 randomized trial.
Circulation. 1991;83:1543-1556.
25.
Walker SH, Duncan DB. Estimation of the probability of an
event as a function of several independent variables.
Biometrika. 1967;54:167-179.
26. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley & Sons, Inc; 1989.
27. Harrell FE Jr, Pollock BG, Lee KL. Graphical methods for the analysis of survival data. Proc 12th Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc; 1987:1107-1115.
28. Smith PL. Splines as a useful and convenient statistical tool. Am Statistician. 1979;33:57-62.
29. Stone CJ, Koo C. Additive splines in statistics. Proc Statistical Computing Section. Alexandria, Va: American Statistical Association: 1985:45-48.
30. Devlin TF, Weeks BJ. Spline functions for logistic regression modeling. Proc 11th Annual SAS Users Group International Conference. Cary, NC: SAS Institute Inc: 1986:646-651.
31.
Harrell FE Jr, Lee KL, Pollock BG. Regression models in
clinical studies: determining relationships between predictors and
response. J Natl Cancer Inst. 1988;80:1198-1202.
32. Chambers JM, Hastie TJ. Statistical Models in S. Pacific Grove, Calif: Wadsworth & Brooks/Cole; 1992.
33. Harrell FE Jr. Transcan: S function for transformation and imputation using canonical variates. Available from statlibalib.stat.cmu. edu; 1993. Request `send transcan from S.'
34. Kuhfeld WF. The PRINQUAL procedure. In: SAS/STAT User's Guide. Cary, NC: SAS Institute, Inc; 1990;2:1265-1323.
35. Efron B. Estimating the error rate of a prediction role: improvement on cross-validation. J Am Statist Assn. 1983;78:316-331.
36. Gong G. Cross-validation, the jackknife, and the bootstrap: excess error estimation in forward logistic regression. J Am Statist Assn. 1986;81:108-113.
37. Efron B. How biased is the apparent error rate of a prediction rule? J Am Statist Assn. 1986;81:461-470.
38. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Am Statistician. 1983;37:36-48.
39. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman and Hall; 1993.
40. Harrell FE Jr. Design: S functions for biostatistical/epidemiologic modeling, testing, estimation, validation, graphics, and prediction. Available from statlibalib.stat.cmu.edu; 1994. Request `send design from S.'
41.
Hanley JA, McNeil BJ. The meaning and use of the area under a
receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36.
42. Kendall DG. Rank Correlation Methods. 3rd ed. London: Charles Griffin; 1962.
43. Yates JF. Judgment and Decision Making. Englewood Cliffs, NJ: Prentice Hall; 1990.
44. Lincoff AM, Califf RM, Ellis SG, Sigmon KN, Lee KL, Leimberger JD, Topol EJ, for the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? J Am Coll Cardiol. 1993;22:1780-1787. [Abstract]
45.
Becker RC, Terrin M, Ross R, Knatterud GL, Desvigne-Nickens P,
Gore JM, Braunwald E, for the Thrombolysis in Myocardial Infarction
Investigators. Comparison of clinical outcomes for women and men after
acute myocardial infarction. Ann Intern Med. 1994;120:638-645.
46.
White HD, Barbash GI, Modan M, Simes J, Diaz R, Hampton JR,
Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EAC, Van der Werf T,
Pehrsson K, Sandoe E, Wilcox RG, Verstraete M, von der Lippe G, Van de
Werf F, for the Investigators of the International Tissue Plasminogen
Activator/Streptokinase Mortality Study. After correcting for worse
baseline characteristics, women treated with thrombolytic therapy for
acute myocardial infarction have the same mortality and morbidity as
men except for a higher incidence of hemorrhagic stroke.
Circulation. 1993;88:2097-2103.
47. Crimm A, Severance HW Jr, Coffey K, McKinnis R, Wagner GS, Califf RM. Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. Am J Med. 1984;73:983-988.
48.
Taylor GJ, Humphries JO, Millits ED, Pitt B, Schulze RA,
Griffith LS, Achuff SC. Predictors of clinical course, coronary anatomy
and left ventricular function after recovery from acute myocardial
infarction. Circulation. 1980;62:960-970.
49. Stone PH, Raabe DS, Jaffe AS, Gustafson N, Muller JE, Turi ZG, Rutherford JD, Poole WK, Passamani E, Willerson JT, Sobel BE, Robertson T, Braunwald E, for the MILIS Group. Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol. 1988;11:453-463. [Abstract]
50. Mauri F, Gasparini M, Barbonaglia L, Santoro E, Franzosi KMG, Tognoni G, Rovelli F. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI Trial). Am J Cardiol. 1989;63:1291-1295. [Medline] [Order article via Infotrieve]
51.
The Dutch TIA Trial Study Group. Predictors of major vascular
events in patients with a transient ischemic attack or nondisabling
stroke. Stroke. 1993;24:527-531.
52. Kornowski R, Goldbourt U, Zion M, Mandelzweig L, Kaplinsky E, Levo Y, Behar S, for the SPRINT Study Group. Predictors and long-term prognostic significance of recurrent infarction in the year after a first myocardial infarction. Am J Cardiol. 1993;72:883-888. [Medline] [Order article via Infotrieve]
53. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. J Am Coll Cardiol. 1993;21:920-925.[Abstract]
54. Barbash GI, White HD, Modan M, Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol. 1993;22:707-713. [Abstract]
55.
Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J,
Kristinsson A, Moulopoulos S, Paolasso EAC, Van der Werf T, Pehrsson K,
Sandoe E, Simes J, Wilcox RG, Verstraete M, Von der Lippe G, Van de
Werf F. Significance of smoking in patients receiving thrombolytic
therapy for acute myocardial infarction: experience gleaned from the
International Tissue Plasminogen Activator/Streptokinase Mortality
Trial. Circulation. 1993;87:53-58.
56.
Ockene IS, Ockene JK. Smoking after acute myocardial
infarction: a good thing? Circulation. 1993;87:297-299.
57. Weaver WD, Litwin PE, Martin JS, Kudenchuk PJ, Maynard C, Eisenberg MS, Ho MT, Cobb LA, Kennedy JW, Wirkus MS, for the MITI Project Group. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol. 1991;18:657-672. [Abstract]
58. Cragg DR, Friedman HZ, Bonema JD, Jaiyesimi IA, Ramos RG, Timmis GC, O'Neill WW, Schreiber TL. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med. 1991;115:173-177.
59. Cairns CB, Niemann JT, Selker HP, Laks MM. Computerized version of the time-insensitive predictive instrument: use of the Q wave, ST-segment, T wave and patient history in the diagnosis of acute myocardial infarction by the computerized ECG. J Electrocardiol. 1992;24:46-49.
60. Muller DW, Topol EJ, Ellis SG, Sigmon KN, Lee K, Califf RM, for the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Am Heart J. 1991;121:1042-1049. [Medline] [Order article via Infotrieve]
61.
Grines CL, Topol EJ, Califf RM, Stack RS, George BS,
Kereiakes D, Boswick JM, Kline E, O'Neill WW, for the TAMI Study
Group. Prognostic implications and predictors of enhanced regional wall
motion of the noninfarct zone after thrombolysis and angioplasty
therapy of acute myocardial infarction.
Circulation. 1989;80:245-253.
62. Tcheng JE, Jackman JD Jr, Nelson CL, Gardner LH, Smith LR, Rankin JS, Califf RM, Stack RS. Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. Ann Intern Med. 1992;117:18-24.
63.
The GUSTO-I Angiographic Investigators. The effects of tissue
plasminogen activator, streptokinase, or both on coronary artery
patency, ventricular function, and survival after acute myocardial
infarction. N Engl J Med. 1993;329:1615-1622.
This article has been cited by other articles:
 |
|
 |
|
  J M Wilson Diagnosis and treatment of acquired coronary artery disease in adults Postgrad. Med. J., July 1, 2009; 85(1005): 364 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J Kurz, A Bernstein, K Hunt, D Radovanovic, P Erne, Z Siudak, and O Bertel Simple point-of-care risk stratification in acute coronary syndromes: the AMIS model Heart, April 1, 2009; 95(8): 662 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C P Gale, S O M Manda, C F Weston, J S Birkhead, P D Batin, and A S Hall Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial Infarction National Audit Project (MINAP) database Heart, February 1, 2009; 95(3): 221 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Danchin, E. Durand, and D. Blanchard Pre-hospital thrombolysis in perspective Eur. Heart J., December 1, 2008; 29(23): 2835 - 2842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: Eur. Heart J., December 1, 2008; 29(23): 2909 - 2945. [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Parikh, S. G. Coca, Y. Wang, F. A. Masoudi, and H. M. Krumholz Long-term Prognosis of Acute Kidney Injury After Acute Myocardial Infarction Arch Intern Med, May 12, 2008; 168(9): 987 - 995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. McDonald, Y. Fu, U. Zeymer, G. Wagner, S. G. Goodman, A. Ross, C. B. Granger, F. Van de Werf, P. W. Armstrong, and for the ASSENT-4 PCI Investigators Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy Eur. Heart J., April 1, 2008; 29(7): 871 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Lewis, E. J. Velazquez, S. D. Solomon, A. S. Hellkamp, J. J.V. McMurray, J. Mathias, J.-L. Rouleau, A. P. Maggioni, K. Swedberg, L. Kober, et al. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study Eur. Heart J., March 2, 2008; 29(6): 748 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guazzi, R. Arena, and M. D. Guazzi Evolving changes in lung interstitial fluid content after acute myocardial infarction: mechanisms and pathophysiological correlates Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1357 - H1364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Berger, A. Stebbins, C. B. Granger, E. M. Ohman, P. W. Armstrong, F. Van de Werf, H. D. White, R. J. Simes, R. A. Harrington, R. M. Califf, et al. Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy Circulation, January 15, 2008; 117(2): 192 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Blasko, R. Kolka, P. Thorbjornsdottir, S. T. Sigurtharson, G. Sigurthsson, Z. Ronai, M. Sasvari-Szekely, S. Bothvarsson, G. Thorgeirsson, Z. Prohaszka, et al. Low complement C4B gene copy number predicts short-term mortality after acute myocardial infarction Int. Immunol., January 1, 2008; 20(1): 31 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Q Khan, P Quinn, J E Davies, and L L Ng N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction Heart, January 1, 2008; 94(1): 40 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jahangir, S. Sagar, and A. Terzic Aging and cardioprotection J Appl Physiol, December 1, 2007; 103(6): 2120 - 2128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Tjandrawidjaja, Y. Fu, H. Al-Khalidi, T. G. Todaro, P. Adams, F. Van de Werf, C. B. Granger, P. W. Armstrong, and on behalf of the APEX-AMI Investigators Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI Eur. Heart J., December 1, 2007; 28(23): 2850 - 2857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kempf, E. Bjorklund, S. Olofsson, B. Lindahl, T. Allhoff, T. Peter, J. Tongers, K. C. Wollert, and L. Wallentin Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction Eur. Heart J., December 1, 2007; 28(23): 2858 - 2865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Lichtman, J. A. Spertus, K. J. Reid, M. J. Radford, J. S. Rumsfeld, N. B. Allen, F. A. Masoudi, W. S. Weintraub, and H. M. Krumholz Acute Noncardiac Conditions and In-Hospital Mortality in Patients With Acute Myocardial Infarction Circulation, October 23, 2007; 116(17): 1925 - 1930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Buxton, K. L. Lee, G. E. Hafley, L. A. Pires, J. D. Fisher, M. R. Gold, M. E. Josephson, M. H. Lehmann, E. N. Prystowsky, and for the MUSTT Investigators Limitations of Ejection Fraction for Prediction of Sudden Death Risk in Patients With Coronary Artery Disease: Lessons From the MUSTT Study J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1150 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Westerhout, M. S. Lauer, S. James, Y. Fu, L. Wallentin, P. W. Armstrong, and for the GUSTO IV ACS Investigators Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women Eur. Heart J., September 1, 2007; 28(17): 2064 - 2069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Fox, J. S. Borer, A. J. Camm, N. Danchin, R. Ferrari, J. L. Lopez Sendon, P. G. Steg, J.-C. Tardif, L. Tavazzi, M. Tendera, et al. Resting Heart Rate in Cardiovascular Disease J. Am. Coll. Cardiol., August 28, 2007; 50(9): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Giraldez, J. C. Nicolau, R. Corbalan, E. P. Gurfinkel, U. Juarez, J. Lopez-Sendon, A. Parkhomenko, P. Molhoek, S. Mohanavelu, D. A. Morrow, et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis Eur. Heart J., July 1, 2007; 28(13): 1566 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Alexander, L. K. Newby, P. W. Armstrong, C. P. Cannon, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al. Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology Circulation, May 15, 2007; 115(19): 2570 - 2589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Mehta, S. Milford-Beland, E. D. Peterson, D. L. Bhatt, M. E. Farkouh, G. X. Brogan, W. B. Gibler, E. M. Ohman, and M. T. Roe Characterizing Young Patients With Diabetes and Non-ST-Segment Elevation Acute Coronary Syndromes Diabetes Care, March 1, 2007; 30(3): 731 - 733. [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Jones, V. Yiannibas, C. Johnson, and J. A. Kline Emergency Department Hypotension Predicts Sudden Unexpected In-hospital Mortality: A Prospective Cohort Study. Chest, October 1, 2006; 130(4): 941 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Armstrong and WEST Steering Committee A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study Eur. Heart J., July 1, 2006; 27(13): 1530 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F Potthoff, G. E Tudor, K. S Pieper, and V. Hasselblad Can one assess whether missing data are missing at random in medical studies? Statistical Methods in Medical Research, June 1, 2006; 15(3): 213 - 234. [Abstract] [PDF]
|
|
|
|
|
|
A. Goyal, K. W. Mahaffey, J. Garg, J. C. Nicolau, J. S. Hochman, W. D. Weaver, P. Theroux, G. B.F. Oliveira, T. G. Todaro, C. F. Mojcik, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study Eur. Heart J., June 1, 2006; 27(11): 1289 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E Bjorklund, T Jernberg, P Johanson, P Venge, M Dellborg, L Wallentin, B Lindahl, and the ASSENT-2 and ASSENT-PLUS Study Groups Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction Heart, June 1, 2006; 92(6): 735 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Pearte, C. D. Furberg, E. S. O'Meara, B. M. Psaty, L. Kuller, N. R. Powe, and T. Manolio Characteristics and Baseline Clinical Predictors of Future Fatal Versus Nonfatal Coronary Heart Disease Events in Older Adults: The Cardiovascular Health Study Circulation, May 9, 2006; 113(18): 2177 - 2185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bjorklund, U. Stenestrand, J. Lindback, L. Svensson, L. Wallentin, B. Lindahl, and on behalf of the RIKS-HIA Investigators Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction Eur. Heart J., May 2, 2006; 27(10): 1146 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Wiviott, D. A. Morrow, P. D. Frederick, E. M. Antman, and E. Braunwald Application of the Thrombolysis In Myocardial Infarction Risk Index in Non-ST-Segment Elevation Myocardial Infarction: Evaluation of Patients in the National Registry of Myocardial Infarction J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1553 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rosengren, L. Wallentin, M. Simoons, A. K Gitt, S. Behar, A. Battler, and D. Hasdai Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey Eur. Heart J., April 1, 2006; 27(7): 789 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Orlandini, R. Diaz, D. Wojdyla, K. Pieper, F. Van de Werf, C. B. Granger, R. A. Harrington, E. Boersma, R. M. Califf, P. Armstrong, et al. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes Eur. Heart J., March 1, 2006; 27(5): 527 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B A Williams, R S Wright, J G Murphy, E S Brilakis, G S Reeder, and A S Jaffe A new simplified immediate prognostic risk score for patients with acute myocardial infarction Emerg. Med. J., March 1, 2006; 23(3): 186 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xu, I. A. Arenas, S. J. Armstrong, W. C. Plahta, H. Xu, and S. T. Davidge Estrogen improves cardiac recovery after ischemia/reperfusion by decreasing tumor necrosis factor-{alpha} Cardiovasc Res, March 1, 2006; 69(4): 836 - 844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-C. Chang, P. Kaul, Y. Fu, C. M. Westerhout, C. B. Granger, K. W. Mahaffey, L. Wallentin, F. Van de Werf, P. W. Armstrong, and for the ASSENT-3 Investigators Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction Eur. Heart J., February 2, 2006; 27(4): 419 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Chen, G. Yang, M. Zhou, M. Smith, A. Offer, J. Ma, L. Wang, H. Pan, G. Whitlock, R. Collins, et al. Body mass index and mortality from ischaemic heart disease in a lean population: 10 year prospective study of 220 000 adult men Int. J. Epidemiol., February 1, 2006; 35(1): 141 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Hernandez, E. J. Velazquez, S. D. Solomon, R. Kilaru, R. Diaz, C. M. O'Connor, G. Ertl, A. P. Maggioni, J.-L. Rouleau, W. van Gilst, et al. Left Ventricular Assessment in Myocardial Infarction: The VALIANT Registry Arch Intern Med, October 10, 2005; 165(18): 2162 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.G. Lindholm, S. Boesgaard, C. Torp-Pedersen, L. Kober, and on behalf of the TRACE registry study group Diabetes mellitus and cardiogenic shock in acute myocardial infarction Eur J Heart Fail, August 1, 2005; 7(5): 834 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Moriel, S. Behar, D. Tzivoni, H. Hod, V. Boyko, and S. Gottlieb Management and Outcomes of Elderly Women and Men With Acute Coronary Syndromes in 2000 and 2002 Arch Intern Med, July 11, 2005; 165(13): 1521 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Figueras, C Pena, and J Soler-Soler Thirty day prognosis of patients with acute pulmonary oedema complicating acute coronary syndromes Heart, July 1, 2005; 91(7): 889 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Halkin, M. Singh, E. Nikolsky, C. L. Grines, J. E. Tcheng, E. Garcia, D. A. Cox, M. Turco, T. D. Stuckey, Y. Na, et al. Prediction of Mortality After Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: The CADILLAC Risk Score J. Am. Coll. Cardiol., May 3, 2005; 45(9): 1397 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Mehta, J. H. Alexander, F. Van de Werf, P. W. Armstrong, K. S. Pieper, J. Garg, R. M. Califf, and C. B. Granger Relationship of Incorrect Dosing of Fibrinolytic Therapy and Clinical Outcomes JAMA, April 13, 2005; 293(14): 1746 - 1750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Suleiman, H. Hammerman, M. Boulos, M. R. Kapeliovich, A. Suleiman, Y. Agmon, W. Markiewicz, and D. Aronson Fasting Glucose Is an Important Independent Risk Factor for 30-Day Mortality in Patients With Acute Myocardial Infarction: A Prospective Study Circulation, February 15, 2005; 111(6): 754 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bursi, M. Enriquez-Sarano, V. T. Nkomo, S. J. Jacobsen, S. A. Weston, R. A. Meverden, and V. L. Roger Heart Failure and Death After Myocardial Infarction in the Community: The Emerging Role of Mitral Regurgitation Circulation, January 25, 2005; 111(3): 295 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Bobba and E. L. Arsura Blood Glucose Level as a Risk Indicator of Death After Acute Myocardial Infarction Arch Intern Med, December 13, 2004; 164(22): 2500 - 2500. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Murcia, C. H. Hennekens, G. A. Lamas, M. Jimenez-Navarro, J. L. Rouleau, G. C. Flaker, S. Goldman, H. Skali, E. Braunwald, and M. A. Pfeffer Impact of Diabetes on Mortality in Patients With Myocardial Infarction and Left Ventricular Dysfunction Arch Intern Med, November 8, 2004; 164(20): 2273 - 2279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Velazquez, G. S. Francis, P. W. Armstrong, P. E. Aylward, R. Diaz, C. M. O'Connor, H. D. White, M. Henis, L. M. Rittenhouse, R. Kilaru, et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry Eur. Heart J., November 1, 2004; 25(21): 1911 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Heggunje, K. J. Harjai, G. W. Stone, R. H. Mehta, D. L. Marsalese, J. A. Boura, W. W. O'Neill, and C. L. Grines Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1400 - 1407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Anavekar, J. J.V. McMurray, E. J. Velazquez, S. D. Solomon, L. Kober, J.-L. Rouleau, H. D. White, R. Nordlander, A. Maggioni, K. Dickstein, et al. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction N. Engl. J. Med., September 23, 2004; 351(13): 1285 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Lim, R. J. MacFadyen, and G. Y. H. Lip Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart Arch Intern Med, September 13, 2004; 164(16): 1737 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Leung, T. H. Rainer, F.-L. Lau, I. O.L. Wong, A. Tong, T.-W. Wong, J. H.B. Kong, A. J. Hedley, T.-H. Lam, and for the Hospital Authority SARS Collaborative Grou A Clinical Prediction Rule for Diagnosing Severe Acute Respiratory Syndrome in the Emergency Department Ann Intern Med, September 7, 2004; 141(5): 333 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 549S - 575S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Wiviott, D. A. Morrow, P. D. Frederick, R. P. Giugliano, C.M. Gibson, C. H. McCabe, C. P. Cannon, E. M. Antman, and E. Braunwald Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: A simple index that predicts mortality in ST-segment elevation myocardial infarction J. Am. Coll. Cardiol., August 18, 2004; 44(4): 783 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Committee Members, E. M. Antman, D. T. Anbe, P. W. Armstrong, E. R. Bates, L. A. Green, M. Hand, J. S. Hochman, H. M. Krumholz, F. G. Kushner, et al. ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction--executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) J. Am. Coll. Cardiol., August 4, 2004; 44(3): 671 - 719. [Full Text] [PDF]
|
|
|
|
|
|
E. M. Antman, D. T. Anbe, P. W. Armstrong, E. R. Bates, L. A. Green, M. Hand, J. S. Hochman, H. M. Krumholz, F. G. Kushner, G. A. Lamas, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation, August 3, 2004; 110(5): 588 - 636. [Full Text] [PDF]
|
|
|
|
|
|
R. Fincke, J. S. Hochman, A. M. Lowe, V. Menon, J. N. Slater, J. G. Webb, T. H. LeJemtel, G. Cotter, and SHOCK Investigators Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry J. Am. Coll. Cardiol., July 21, 2004; 44(2): 340 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-C. Wu and P. C. Gordon Invasive Management of Patients With ST Elevation Myocardial Infarction With > 12-h Delay in Presentation: The Question Remains Unanswered Chest, July 1, 2004; 126(1): 2 - 4. [Full Text] [PDF]
|
|
|
|
|
|
K. A. Eagle, M. J. Lim, O. H. Dabbous, K. S. Pieper, R. J. Goldberg, F. Van de Werf, S. G. Goodman, C. B. Granger, P. G. Steg, J. M. Gore, et al. A Validated Prediction Model for All Forms of Acute Coronary Syndrome: Estimating the Risk of 6-Month Postdischarge Death in an International Registry JAMA, June 9, 2004; 291(22): 2727 - 2733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. De Luca, H. Suryapranata, A. W.J. van't Hof, M.-J. de Boer, J. C.A. Hoorntje, J.-H. E. Dambrink, A.T. M. Gosselink, J. P. Ottervanger, and F. Zijlstra Prognostic Assessment of Patients With Acute Myocardial Infarction Treated With Primary Angioplasty: Implications for Early Discharge Circulation, June 8, 2004; 109(22): 2737 - 2743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Madias The Impact of Systemic BP on Coronary Blood Flow and Infarct Size During Reperfusion Therapy for Acute Myocardial Infarction: Refinements Beyond the "Plumbing" Chest, April 1, 2004; 125(4): 1179 - 1181. [Full Text] [PDF]
|
|
|
|
|
|
J. N. Nanas, E. Tsolakis, J. V. Terrovitis, A. Eleftheriou, S. G. Drakos, A. Dalianis, and C. E. Charitos Moderate Systemic Hypotension During Reperfusion Reduces the Coronary Blood Flow and Increases the Size of Myocardial Infarction in Pigs Chest, April 1, 2004; 125(4): 1492 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Velazquez and M. A. Pfeffer Acute Heart Failure Complicating Acute Coronary Syndromes: A Deadly Intersection Circulation, February 3, 2004; 109(4): 440 - 442. [Full Text] [PDF]
|
|
|
|
|
|
P. G. Steg, O. H. Dabbous, L. J. Feldman, A. Cohen-Solal, M.-C. Aumont, J. Lopez-Sendon, A. Budaj, R. J. Goldberg, W. Klein, F. A. Anderson Jr, et al. Determinants and Prognostic Impact of Heart Failure Complicating Acute Coronary Syndromes: Observations From the Global Registry of Acute Coronary Events (GRACE) Circulation, February 3, 2004; 109(4): 494 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bjorklund, B. Lindahl, P. Johanson, T. Jernberg, A.-M. Svensson, P. Venge, L. Wallentin, M. Dellborg, and the ASSENT-2 and ASSENT-PLUS study groups Admission Troponin T and measurement of ST-segment resolution at 60 min improve early risk stratification in ST-elevation myocardial infarction Eur. Heart J., January 2, 2004; 25(2): 113 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Lee, P. C. Austin, J. L. Rouleau, P. P. Liu, D. Naimark, and J. V. Tu Predicting Mortality Among Patients Hospitalized for Heart Failure: Derivation and Validation of a Clinical Model JAMA, November 19, 2003; 290(19): 2581 - 2587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Granger, R. J. Goldberg, O. Dabbous, K. S. Pieper, K. A. Eagle, C. P. Cannon, F. Van de Werf, A. Avezum, S. G. Goodman, M. D. Flather, et al. Predictors of Hospital Mortality in the Global Registry of Acute Coronary Events Arch Intern Med, October 27, 2003; 163(19): 2345 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. N. Khot, G. Jia, D. J. Moliterno, A. M. Lincoff, M. B. Khot, R. A. Harrington, and E. J. Topol Prognostic Importance of Physical Examination for Heart Failure in Non-ST-Elevation Acute Coronary Syndromes: The Enduring Value of Killip Classification JAMA, October 22, 2003; 290(16): 2174 - 2181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. L Williams, B. Noronha, and A. G Zaman Review: The management of acute myocardial infarction in patients with diabetes mellitus The British Journal of Diabetes & Vascular Disease, September 1, 2003; 3(5): 319 - 324. [Abstract] [PDF]
|
|
|
|
|
|
E. J. Velazquez, M. A. Pfeffer, J. V. McMurray, A. P. Maggioni, J.-L. Rouleau, F. Van de Werf, L. Kober, H. D. White, K. Swedberg, J. D. Leimberger, et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context Eur J Heart Fail, August 1, 2003; 5(4): 537 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Tjandrawidjaja, Y. Fu, S. G. Goodman, F. Van de Werf, C. B. Granger, P. W. Armstrong, and for the ASSENT-2 Investigators The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2{star} Eur. Heart J., June 1, 2003; 24(11): 1024 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P.S. Henriques, F. Zijlstra, M.-J. de Boer, A. W.J. van't Hof, A.T. M. Gosselink, J.-H. E. Dambrink, H. Suryapranata, and J. C.A. Hoorntje The prognostic importance of heart failure and age in patients treated with primary angioplasty Eur J Heart Fail, June 1, 2003; 5(3): 291 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Foo, J Cooper, A Deaner, C Knight, A Suliman, K Ranjadayalan, and A D Timmis A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes Heart, May 1, 2003; 89(5): 512 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.A. Pfeffer The intersection between acute coronary syndrome and heart failure Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C19 - C23. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Lauzon, C. A. Beck, T. Huynh, D. Dion, N. Racine, S. Carignan, J. G. Diodati, F. Charbonneau, R. Dupuis, and L. Pilote Depression and prognosis following hospital admission because of acute myocardial infarction Can. Med. Assoc. J., March 4, 2003; 168(5): 547 - 552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. TU and C. CAMERON Impact of an acute myocardial infarction report card in Ontario, Canada Int. J. Qual. Health Care, March 1, 2003; 15(2): 131 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. SCOTT, K. HEATH, C. HARPER, and A. CLOUGH An Australian comparison of specialist care of acute myocardial infarction Int. J. Qual. Health Care, March 1, 2003; 15(2): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.K Newby, M.V Bhapkar, H.D White, E.J Topol, F.C Dougherty, R.A Harrington, M.C Smith, L.F Asarch, R.M Califf, and for the SYMPHONY and 2nd SYMPHONY Investigators Predictors of 90-day outcome in patients stabilized after acute coronary syndromes Eur. Heart J., January 2, 2003; 24(2): 172 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Task Force on the Management of Acute Myocardi, F. Van de Werf, D. Ardissino, A. Betriu, D. V. Cokkinos, E. Falk, K. A.A. Fox, D. Julian, M. Lengyel, F.-J. Neumann, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation Eur. Heart J., January 1, 2003; 24(1): 28 - 66. [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Willerson Myocardial Revascularization with Cardiologic Interventional Devices Card. Surg. Adult, January 1, 2003; 2(2003): 561 - 580. [Full Text]
|
|
|
|
|
|
C-K Wong and H D White Relation between blood pressure after an acute coronary event and subsequent cardiovascular risk Heart, December 1, 2002; 88(6): 555 - 558. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Wu, L. Parsons, N. R. Every, and E. R. Bates Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2) J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Mehta, D. A. Criger, C. B. Granger, K. K. Pieper, R. M. Califf, E. J. Topol, and E. R. Bates Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1034 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L F Hsu, K H Mak, K W Lau, L L Sim, C Chan, T H Koh, S C Chuah, R Kam, Z P Ding, W S Teo, et al. Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis Heart, September 1, 2002; 88(3): 260 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Al Suwaidi, D. N. Reddan, K. Williams, K. S. Pieper, R. A. Harrington, R. M. Califf, C. B. Granger, E. M. Ohman, D. R. Holmes Jr, and for the GUSTO-IIb, GUSTO-III, PURSUIT, and PARAGON Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes Circulation, August 20, 2002; 106(8): 974 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Grines, D. R. Westerhausen Jr, L. L. Grines, J. T. Hanlon, T. L. Logemann, M. Niemela, W. D. Weaver, M. Graham, J. Boura, W. W. O'Neill, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: The air primary angioplasty in myocardial infarction study J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1713 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfeffer and J. J.V. McMurray Myocardial Infarct: No One Size Fits All Circulation, June 4, 2002; 105(22): 2577 - 2579. [Full Text] [PDF]
|
|
|
|
|
|
F. Mauri, M. G. Franzosi, A. P. Maggioni, E. Santoro, and L. Santoro Clinical value of 12-lead electrocardiography to predict the long-term prognosis of gissi-1 patients J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1594 - 1600. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||